Qian Fenghua, Fan Wenxia, Wei Xia, Zhu Yan, Fu Gang, Qin Dabing, Tian Xiaobo, Pei Li, Xu Shuangnian, Chen Jieping, Zhang Yong
Department of Hematology, Southwestern Hospital, Third Military Medical University, Chongqing, China (mainland).
Ann Transplant. 2015 Apr 23;20:225-32. doi: 10.12659/AOT.892975.
BacKGROUND: Hematopoietic stem cell transplantation (HSCT) is considered to be a cure for lymphoma. However, factors related to its prognosis remain unclear.
Eighty patients diagnosed with lymphoma and treated with autologous HSCT (Auto HSCT) were recruited. The primary endpoints included overall survival (OS) and progression-free survival (PFS).
After a median follow-up of 37.9 months, the 3-year OS was 75%. Univariate analysis showed age (P=0.020), elevated lactate dehydrogenase (LDH) (P=0.031), international prognostic index (IPI) (P=0.015), Eastern Cooperative Oncology Group (ECOG) (P=0.048), bone marrow involvement (P=0.038), and time to neutrophil recovery (P=0.043) were prognostic factors of lymphoma. Multivariate analysis revealed IPI (hazard ratio [HR] 1.60, 95% confidence interval [CI] 1.09-2.34, P=0.016) and time to neutrophil recovery (HR 2.69, 95% CI 1.02-7.07, P=0.045) were independent factors correlated with OS.
IPI and neutrophil recovery are recommendatory predictors for lymphoma patients after Auto HSCT.
背景：造血干细胞移植（HSCT）被认为是淋巴瘤的一种治愈方法。然而，与其预后相关的因素仍不清楚。
招募了80例诊断为淋巴瘤并接受自体HSCT（自体造血干细胞移植）治疗的患者。主要终点包括总生存期（OS）和无进展生存期（PFS）。
中位随访37.9个月后，3年总生存率为75%。单因素分析显示年龄（P=0.020）、乳酸脱氢酶（LDH）升高（P=0.031）、国际预后指数（IPI）（P=0.015）、东部肿瘤协作组（ECOG）评分（P=0.048）、骨髓受累（P=0.038）以及中性粒细胞恢复时间（P=0.043）是淋巴瘤的预后因素。多因素分析显示IPI（风险比[HR]1.60，95%置信区间[CI]1.09 - 2.34，P=0.016）和中性粒细胞恢复时间（HR 2.69，95%CI 1.02 - 7.07，P=0.045）是与总生存期相关的独立因素。
IPI和中性粒细胞恢复是自体HSCT后淋巴瘤患者的推荐预测指标。
Zotero 插件